• N Plevris, C S Chuah, R M Allen, I D Arnott, P N Brennan, S Chaudhary, A M D Churchhouse, S Din, E Donoghue, D R Gaya, M Groome, H M Jafferbhoy, P W Jenkinson, W L Lam, M Lyons, J C Macdonald, M MacMaster, C Mowat, G D Naismith, L F Potts, E Saffouri, J P Seenan, A Sengupta, P Shasi, D I Sutherland, J A Todd, J Veryan, Watson A J M AJM Department of Colorectal Surgery, Raigmore Hospital, Inverness, UK., D A Watts, G R Jones, and C W Lees.
• The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK.
• J Crohns Colitis. 2019 Sep 19; 13 (9): 1111-1120.

Background & AimsVedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis. The aims of this study were to establish the real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease.MethodsThis was a retrospective study involving seven NHS health boards in Scotland between June 2015 and November 2017. Inclusion criteria included: a diagnosis of ulcerative colitis or Crohn's disease with objective evidence of active inflammation at baseline (Harvey-Bradshaw Index[HBI] ≥5/Partial Mayo ≥2 plus C-reactive protein [CRP] >5 mg/L or faecal calprotectin ≥250 µg/g or inflammation on endoscopy/magnetic resonance imaging [MRI]); completion of induction; and at least one clinical follow-up by 12 months. Kaplan-Meier survival analysis was used to establish 12-month cumulative rates of clinical remission, mucosal healing, and deep remission [clinical remission plus mucosal healing]. Rates of serious adverse events were described quantitatively.ResultsOur cohort consisted of 180 patients with ulcerative colitis and 260 with Crohn's disease. Combined median follow-up was 52 weeks (interquartile range [IQR] 26-52 weeks). In ulcerative colitis, 12-month cumulative rates of clinical remission, mucosal healing, and deep remission were 57.4%, 47.3%, and 38.5%, respectively. In Crohn's disease, 12-month cumulative rates of clinical remission, mucosal healing, and deep remission were 58.4%, 38.9%, and 28.3% respectively. The serious adverse event rate was 15.6 per 100 patient-years of follow-up.ConclusionsVedolizumab is a safe and effective treatment for achieving both clinical remission and mucosal healing in ulcerative colitis and Crohn's disease.Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

37 keywords...

hide…